Nektar Therapeutics (NKTR): A Bull Case Theory
We came across a bullish thesis on Nektar Therapeutics on Clinical Catalysts’s Substack. In this article, we will summarize the bulls’ thesis on NKTR.
Nektar Therapeutics (NKTR)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Biotechnology Value Fund / BVF Inc Mark Lampert | 1,559,595 | $65,939,677 | +23% | 2.22% |
| 2. | Two Seas Capital Sina Toussi | 745,185 | $31,506,422 | 0.65% | |
| 3. | Armistice Capital Steven Boyd | 596,000 | $25,198,880 | +123% | 0.3% |
| 4. | Prosight Capital Lawrence Hawkins | 554,633 | $23,449,883 | 4.85% | |
| 5. | Millennium Management Israel Englander | 454,075 | $19,198,291 | -17% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.28 | 15,000 | $259,200.00 | 107,668 | 2019-09-05 | Filing | |
| $59.80 | 1,400 | $83,720.00 | 177,000 | 2018-06-06 | Filing | |
| $59.07 | 2,000 | $118,140.00 | 175,600 | 2018-06-06 | Filing | |
| $55.22 | 1,600 | $88,352.00 | 173,600 | 2018-06-05 | Filing | |
| $17.95 | 35,000 | $628,250.00 | 133,000 | 2017-08-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $35.67 | 3,867 | $137,935.89 | 21,354 | 2026-01-20 | Filing | |
| $54.28 | 1,157 | $62,801.96 | 18,971 | 2025-11-25 | Filing | |
| $54.28 | 630 | $34,196.40 | 21,585 | 2025-11-25 | Filing | |
| $54.28 | 2,207 | $119,795.96 | 54,245 | 2025-11-25 | Filing | |
| $48.18 | 1,210 | $58,297.80 | 49,342 | 2025-09-09 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,027,089 | $43,425,322 | 0% | |
| 2. | 645,607 | $27,296,262 | 0% | |
| 3. | 566,421 | $23,948,280 | 0% | |
| 4. | 473,014 | $19,999,032 | 0.03% | |
| 5. | 438,630 | $18,545,276 | 0.8% |
News See All
Strong REZOLVE-AA Study Results Drive Analyst Confidence in Nektar Therapeutics (NKTR)
The trial narrowly missed its primary endpoint; however, Oppenheimer highlighted that omitting four patients with eligibility violations yielded nominal statistical significance.
12 Best Multibagger Stocks to Buy Heading into 2026
As we head into 2026, the biggest question market participants are asking is whether the strong momentum this year can carry over into next year.
Is Nektar Therapeutics (NKTR) The Hottest SMID-Cap Stock to Buy Now?
Nektar Therapeutics (NASDAQ:NKTR) is among the hottest SMID-cap stocks so far in 2025.
10 Hottest SMID-Cap Stocks So Far In 2025
SMID-caps, or Small- and mid-cap stocks, are often overlooked segments of the market.
Nektar Therapeutics (NASDAQ:NKTR) Q3 2025 Earnings Call Transcript
Operator: Hello, and thank you for standing by. Welcome to the Nektar Therapeutics Third Quarter 2025 Financial Results Conference Call.
Nektar Therapeutics Data from REZOLVE-AD Study Accepted for Late-Breaking Oral Presentation
Nektar Therapeutics (NASDAQ:NKTR) is one of the hot stocks to buy with huge upside potential.
12 Hot Stocks to Buy with Huge Upside Potential
On October 22, Vios Advisors’ Michael Bapis and BNY’s Alicia Levine joined CNBC's 'Closing Bell' to discuss the latest news affecting markets.
Nektar Therapeutics (NASDAQ:NKTR) Q2 2025 Earnings Call Transcript
Operator: Welcome to the Nektar Therapeutics Second Quarter 2025 Financial Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
Nektar Therapeutics (NKTR) Announced Positive results for Rezpegaldesleukin
Nektar Therapeutics (NASDAQ:NKTR) is one of the Stocks With Huge Catalysts on the Horizon. On June 24, Nektar Therapeutics (NASDAQ:NKTR) announced positive results from the Phase 2b REZOLVE-AD trial...
Hedge Fund Resource Center Billionaire Hedge Funds
